References for this Review were identified through searches of PubMed up to December, 2010, with the search terms “APOE AND neurological disorders”, “APOE AND Alzheimer's disease”, “APOE AND drug AND Alzheimer's disease”, “APOE AND cerebral amyloid angiopathy”, “APOE AND traumatic brain injury”, “APOE AND stroke”, “APOE AND Down's syndrome”, “APOE AND vascular dementia”, “APOE AND Lewy body dementia”, “APOE AND inclusion-body myositis”, “APOE AND Creutzfeldt-Jakob disease”, “APOE AND
ReviewApolipoprotein E in Alzheimer's disease and other neurological disorders
Introduction
With few efficacious treatment options available, management of many neurological disorders presents clinicians with substantial challenges, while health-care systems are burdened with enormous strain. Understanding the environmental and genetic components that modulate risks and outcomes of neurological disease could provide useful information about management of these devastating disorders. After a series of landmark studies1, 2, 3, 4, 5 identifying a strong association between presence of the apolipoprotein E (APOE) ɛ4 allele and increased risk of Alzheimer's disease (AD) and decreased age of onset, as well as the protective role of APOE ɛ2, numerous studies have investigated putative associations of APOE genotype with risk or progression of various neurological disorders. Because of the various proposed roles of APOE in amyloid-β metabolism, CNS lipid homoeostasis, synaptic activity, response to cellular injury, and neuroinflammation, these investigations were hypothesised to show strong associations with several diseases. However, so far, evidence for an association between APOE genotype and disease risk and age of onset remains the most compelling for AD and cerebral amyloid angiopathy (CAA). APOE is believed to be linked to risk of these two diseases through isoform-dependent modulation of amyloid-β accumulation. Associations of APOE with outcomes after traumatic brain injury (TBI) or risk of Down's syndrome-associated dementia are also postulated to be, in part, mediated through isoform-dependent modulation of amyloid-β accumulation. Associations between APOE genotype and stroke, vascular dementia, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and other disorders have been suggested, but more research is needed to establish whether APOE has a role in these disorders. In this Review, we aim to assess evidence for associations of APOE genotype with risk and outcomes for various neurological diseases, with particular attention to AD and CAA, for which evidence of an association is strong (table). The many proposed roles of APOE in the nervous system are a challenge to understanding the involvement of this protein in the pathogenesis of neurological diseases and implications for treatment strategies. Here, we also assess differences in treatment response according to APOE status in clinical trials of AD.
Section snippets
Physiological function of APOE
Human APOE is a lipoprotein of 299 aminoacids that is expressed in many organs, with the highest expression in the liver followed by the brain.129 APOE exists mainly as a component of lipoprotein complexes along with other apolipoproteins and proteins in plasma and CSF.129 In humans, there are three major polymorphic forms of APOE: APOE2 (Cys112, Cys158), APOE3 (Cys112, Arg158), and APOE4 (Arg112, Arg158).130 Aminoacid differences at these positions are crucial as they alter the charge and
Alzheimer's disease
AD is a devastating neurodegenerative disease affecting about 26 million people worldwide.136 The disease is pathologically defined by extracellular accumulation of amyloid β, intracellular accumulation of tau, neuronal and synaptic loss, brain atrophy, and inflammation.6 Mutations in three genes, APP, PS1, and PS2, cause rare forms of autosomal dominant familial AD with clinical onset typically between the ages of 30–60 years.6 Several susceptibility genes have also been implicated in AD risk,
Traumatic brain injury
Results published over the past two decades have suggested a link between TBI and risk of AD.49, 50, 51 Several groups have reported a strongly increased risk of AD in patients with TBI who have an APOE ɛ4 allele (table).52, 53 One proposed mechanism for the increased development of dementia in patients with TBI is that brain trauma precipitates amyloid-β deposition, which is supported by the increased frequency of amyloid-β deposition identified in post-mortem cortical extracts from patients
Conclusions
Accumulating evidence suggests a central role for APOE in the modulation of processes of neurodegeneration, especially in AD and CAA. A large body of evidence has identified APOE ɛ4 as a major susceptibility factor and modulator of age at onset of AD, whereas APOE ɛ2 seems to confer protection (table). A convincing body of published work suggests that APOE genotype modulates risk of AD largely via amyloid β, probably through isoform-dependent effects on aggregation or clearance from the brain
Search strategy and selection criteria
References (182)
- et al.
Apolipoprotein E polymorphism and Alzheimer's disease
Lancet
(1993) - et al.
Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease
Neurosci Lett
(1994) - et al.
Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study
Lancet Neurol
(2007) - et al.
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1-42
Neurobiol Dis
(2005) - et al.
Cerebrospinal fluid beta-amyloid1–42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE ɛ4 allele
Biol Psychiatry
(2004) - et al.
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
J Lipid Res
(2005) - et al.
Occurrence and co-localization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice
Neurobiol Aging
(2007) - et al.
βA4 amyloid protein deposition in brain after head trauma
Lancet
(1991) - et al.
Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma
Am J Pathol
(2004) - et al.
Association of apolipoprotein E polymorphism with outcome after head injury
Lancet
(1997)